SCHEMBL4241264

SCHEMBL4241264

O=c1c2ccccc2nc(-c2ccc(F)cc2)n1NCc1cccnc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.64
LMNA P02545 3/20 0.51
MAPT P10636 2/20 0.50
HTT P42858 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
ALDH1A1 P00352 9/20 0.49
KMT2A Q03164 3/20 0.48
GAA P10253 2/20 0.48
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MDM2 Q00987 1/20 0.47
POLB P06746 3/20 0.47
MEN1 O00255 2/20 0.47
CYP1A2 P05177 4/20 0.47
CYP2D6 P10635 4/20 0.47
CYP2C19 P33261 4/20 0.47
CYP3A4 P08684 3/20 0.47
CYP2C9 P11712 3/20 0.47
PDE5A O76074 2/20 0.47
RECQL P46063 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13930051 0.84 SMN1; SMN2 (0.68) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4237651 0.83 SMN1; SMN2 (0.67) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4236185 0.83 SMN1; SMN2 (0.67) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4240608 0.82 SMN1; SMN2 (0.66) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4242686 0.81 LMNA (0.65) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4237693 0.81 SMN1; SMN2 (0.64) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4233215 0.80 SMN1; SMN2 (0.63) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4242386 0.80 SMN1; SMN2 (0.63) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4233701 0.80 SMN1; SMN2 (0.63) SMN1; SMN2LMNAMAPTHTTNPSR1
SCHEMBL4237530 0.78 SMN1; SMN2 (0.73) SMN1; SMN2LMNAMAPTHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-05 US disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed
WO-2008067219-A2 QUINAZOLINONE MODULATORS OF TGR5 KALYPSYS, INC. (US) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035306-A1 QUINAZOLINONE MODULATORS OF TGR5 GRK5, PLAAT5, GPBAR1 SMN1; SMN2 4767/4885LMNA 3751/4885MAPT 4430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.